Sfoglia per Autore
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.
2005-01-01 Rossini F;Terruzzi E;Verga L;Larocca A;Marinoni S;Miccolis I;Giltri G;Isella M;Parma M;Pogliani EM
Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation.
2006-01-01 Larocca A;Piaggio G;Podestà M;Pitto A;Bruno B;Di Grazia C;Gualandi F;Occhini D;Raiola AM;Dominietto A;Bregante S;Lamparelli T;Tedone E;Oneto R;Frassoni F;Van Lint MT;Pogliani E;Bacigalupo A
Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m2 in Elderly Newly Diagnosed Patients: An Interim Analysis.
2007-01-01 Palumbo A; Avonto I; Patriarca F; Crippa C; Petrucci MT; Rossini F; Corradini P; Liberati AM; Giuliani N; Pescosta N; Falco P; Larocca A; Omedè P; Offidani M; Fanin R; Boccadoro M
Gammopatie monoclonali
2008-01-01 Mario Boccadoro, Francesca Gay, Alessandra Larocca, Valeria Magarotto, Antonio Palumbo
Defibrotide: a review on clinical use and future development.
2008-01-01 Larocca A;Cavallo F;Magarotto V;Rossi D;Patriarca F;Boccadoro M;Palumbo A
Treatment of newly diagnosed multiple myeloma.
2008-01-01 Palumbo A;Magarotto V;Larocca A;Bringhen S;Falco P;Di Raimondo F;Baldini L;Boccadoro M
Lenalidomide and its role in the management of multiple myeloma
2008-01-01 Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results
2009-01-01 Palumbo A; Falco P; Falcone A; Benevolo G; Canepa L; Gay F; Larocca A; Magarotto V; Gozzetti A; Luraschi A; Morabito F; Nozza A; Knight RD; Zeldis JB; Boccadoro M; Petrucci MT.
ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS
2010-01-01 F Gay; A Larocca; MT Petrucci; P Musto; AM Liberati; V Callea; R Ria; T Caravita; C Cangialosi; M Grasso; M Offidani; P Pregno; F Patriarca; M Galli; M Cavo; L Catalano; C Nozzoli; T Guglielmelli; R Zambello; F Pisani; V Montefusco; F Rossini; V De Stefano; B Lupo; F Di Raimondo; G Gaidano; M Boccadoro; A Palumbo
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
2010-01-01 Palumbo A;Larocca A;Falco P;Sanpaolo G;Falcone AP;Federico V;Canepa L;Crugnola M;Genuardi M;Magarotto V;Petrucci MT;Boccadoro M
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease
2010-01-01 Alberto Rocci; Manuela Gambella; Simona Aschero; Ileana Baldi; Livio Trusolino; Federica Cavallo; Alessandra Larocca; Paola Omedè; Andrea Bertotti; Vittorio Montefusco; Claudia Crippa; Francesca Patriarca; Anna Marina Liberati; Antonietta Falcone; Gianluca Isaia; Daniela Drandi; Marco Ladetto; Paolo M. Comoglio; Giovannino Ciccone; Mario Boccadoro; and Antonio Palumbo
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
2010-01-01 Bringhen S;Larocca A;Rossi D;Cavalli M;Genuardi M;Ria R;Gentili S;Patriarca F;Nozzoli C;Levi A;Guglielmelli T;Benevolo G;Callea V;Rizzo V;Cangialosi C;Musto P;De Rosa L;Liberati AM;Grasso M;Falcone AP;Evangelista A;Cavo M;Gaidano G;Boccadoro M;Palumbo A
A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIB-MELPHALANPREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA:EFFECT OF AGE AND CO-MORBIDITIES
2010-01-01 A Palumbo; S Bringhen; D Rossi; M Cavalli; R Ria; M Offidani; C Nozzoli; L Baldini; L De Rosa; G De Sabbata; AM Liberati; C Crippa; F Ciambelli; V Callea; M Spriano; F Ferrara; F Elice; M Galli; J Peccatori; L Catalano; M Rizzo; R Marasca; F Pisani; M Cavo; M Petrucci; P Musto; P Omedè; A Larocca; G Gaidano; M Boccadoro
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial.
2010-01-01 Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Pia Falcone A; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M.
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.
2010-01-01 Offidani M; Leoni P; Bringhen S; Corvatta L; Larocca A; Gentili S; Oliva S; Polloni C; Galieni P; Catarini M; Alesiani F; Mele A; Brunori M; Blasi N; Ferranti M; Visani G; Boccadoro M; Palumbo A.
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
2010-01-01 Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P; Italian Multiple Myeloma Network GIMEMA.
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens
2011-01-01 Benevolo G; Larocca A; Gentile M; Pregno P; Gay F; Botto B; Frairia C; Evangelista A; Morabito F; Boccadoro M; Vitolo U; Palumbo A.
A PHASE III STUDY OF ENOXAPARIN VS ASPIRIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED OF MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE-BASED REGIMENS.
2011-01-01 F. CAVALLO; T. CARAVITA; F. DI RAIMONDO; G. CICCONE; B. LUPO; M. MARCATTI; A. BARALDI; N. PESCOSTA; A.P. FALCONE ;R. RIA; L. BALDINI; L. MASINI; T. GUGLIELMELLI; G. GAIDANO; G. BENEVOLO; C. CANGIALOSI ; M. GALLI ; L. CATALANO; A. LAROCCA; A. NAGLER; M. BOCCADORO; A. PALUMBO
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.
2011-01-01 Gay F; Larocca A; Wijermans P; Cavallo F; Rossi D; Schaafsma R; Genuardi M; Romano A; Liberati AM; Siniscalchi A; Petrucci MT; Nozzoli C; Patriarca F; Offidani M; Ria R; Omedè P; Bruno B; Passera R; Musto P; Boccadoro M; Sonneveld P; Palumbo A.
Evolving paradigms in the treatment of newly diagnosed multiple myeloma.
2011-01-01 Larocca A;Palumbo A
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. | 2005 | Rossini F;Terruzzi E;Verga L;Larocca A;Marinoni S;Miccolis I;Giltri G;Isella M;Parma M;Pogliani EM | |
Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. | 2006 | Larocca A;Piaggio G;Podestà M;Pitto A;Bruno B;Di Grazia C;Gualandi F;Occhini D;Raiola AM;Dominietto A;Bregante S;Lamparelli T;Tedone E;Oneto R;Frassoni F;Van Lint MT;Pogliani E;Bacigalupo A | |
Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m2 in Elderly Newly Diagnosed Patients: An Interim Analysis. | 2007 | Palumbo A; Avonto I; Patriarca F; Crippa C; Petrucci MT; Rossini F; Corradini P; Liberati AM; Giuliani N; Pescosta N; Falco P; Larocca A; Omedè P; Offidani M; Fanin R; Boccadoro M | |
Gammopatie monoclonali | 2008 | Mario Boccadoro, Francesca Gay, Alessandra Larocca, Valeria Magarotto, Antonio Palumbo | |
Defibrotide: a review on clinical use and future development. | 2008 | Larocca A;Cavallo F;Magarotto V;Rossi D;Patriarca F;Boccadoro M;Palumbo A | |
Treatment of newly diagnosed multiple myeloma. | 2008 | Palumbo A;Magarotto V;Larocca A;Bringhen S;Falco P;Di Raimondo F;Baldini L;Boccadoro M | |
Lenalidomide and its role in the management of multiple myeloma | 2008 | Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A | |
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results | 2009 | Palumbo A; Falco P; Falcone A; Benevolo G; Canepa L; Gay F; Larocca A; Magarotto V; Gozzetti A; Luraschi A; Morabito F; Nozza A; Knight RD; Zeldis JB; Boccadoro M; Petrucci MT. | |
ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS | 2010 | F Gay; A Larocca; MT Petrucci; P Musto; AM Liberati; V Callea; R Ria; T Caravita; C Cangialosi; M Grasso; M Offidani; P Pregno; F Patriarca; M Galli; M Cavo; L Catalano; C Nozzoli; T Guglielmelli; R Zambello; F Pisani; V Montefusco; F Rossini; V De Stefano; B Lupo; F Di Raimondo; G Gaidano; M Boccadoro; A Palumbo | |
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. | 2010 | Palumbo A;Larocca A;Falco P;Sanpaolo G;Falcone AP;Federico V;Canepa L;Crugnola M;Genuardi M;Magarotto V;Petrucci MT;Boccadoro M | |
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease | 2010 | Alberto Rocci; Manuela Gambella; Simona Aschero; Ileana Baldi; Livio Trusolino; Federica Cavallo; Alessandra Larocca; Paola Omedè; Andrea Bertotti; Vittorio Montefusco; Claudia Crippa; Francesca Patriarca; Anna Marina Liberati; Antonietta Falcone; Gianluca Isaia; Daniela Drandi; Marco Ladetto; Paolo M. Comoglio; Giovannino Ciccone; Mario Boccadoro; and Antonio Palumbo | |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. | 2010 | Bringhen S;Larocca A;Rossi D;Cavalli M;Genuardi M;Ria R;Gentili S;Patriarca F;Nozzoli C;Levi A;Guglielmelli T;Benevolo G;Callea V;Rizzo V;Cangialosi C;Musto P;De Rosa L;Liberati AM;Grasso M;Falcone AP;Evangelista A;Cavo M;Gaidano G;Boccadoro M;Palumbo A | |
A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIB-MELPHALANPREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA:EFFECT OF AGE AND CO-MORBIDITIES | 2010 | A Palumbo; S Bringhen; D Rossi; M Cavalli; R Ria; M Offidani; C Nozzoli; L Baldini; L De Rosa; G De Sabbata; AM Liberati; C Crippa; F Ciambelli; V Callea; M Spriano; F Ferrara; F Elice; M Galli; J Peccatori; L Catalano; M Rizzo; R Marasca; F Pisani; M Cavo; M Petrucci; P Musto; P Omedè; A Larocca; G Gaidano; M Boccadoro | |
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. | 2010 | Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Pia Falcone A; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M. | |
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. | 2010 | Offidani M; Leoni P; Bringhen S; Corvatta L; Larocca A; Gentili S; Oliva S; Polloni C; Galieni P; Catarini M; Alesiani F; Mele A; Brunori M; Blasi N; Ferranti M; Visani G; Boccadoro M; Palumbo A. | |
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial | 2010 | Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P; Italian Multiple Myeloma Network GIMEMA. | |
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens | 2011 | Benevolo G; Larocca A; Gentile M; Pregno P; Gay F; Botto B; Frairia C; Evangelista A; Morabito F; Boccadoro M; Vitolo U; Palumbo A. | |
A PHASE III STUDY OF ENOXAPARIN VS ASPIRIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED OF MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE-BASED REGIMENS. | 2011 | F. CAVALLO; T. CARAVITA; F. DI RAIMONDO; G. CICCONE; B. LUPO; M. MARCATTI; A. BARALDI; N. PESCOSTA; A.P. FALCONE ;R. RIA; L. BALDINI; L. MASINI; T. GUGLIELMELLI; G. GAIDANO; G. BENEVOLO; C. CANGIALOSI ; M. GALLI ; L. CATALANO; A. LAROCCA; A. NAGLER; M. BOCCADORO; A. PALUMBO | |
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. | 2011 | Gay F; Larocca A; Wijermans P; Cavallo F; Rossi D; Schaafsma R; Genuardi M; Romano A; Liberati AM; Siniscalchi A; Petrucci MT; Nozzoli C; Patriarca F; Offidani M; Ria R; Omedè P; Bruno B; Passera R; Musto P; Boccadoro M; Sonneveld P; Palumbo A. | |
Evolving paradigms in the treatment of newly diagnosed multiple myeloma. | 2011 | Larocca A;Palumbo A |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile